Wendie A Berg, Jeremy M Berg, Andriy I Bandos, Adrienne Vargo, Denise M Chough, Amy H Lu, Marie A Ganott, Amy E Kelly, Bronwyn E Nair, Jamie Y Hartman, Uzma Waheed, Christiane M Hakim, Kimberly S Harnist, Ruthane F Reginella, Dilip D Shinde, Bea A Carlin, Cathy S Cohen, Luisa P Wallace, Jules H Sumkin, Margarita L Zuley
Background Digital breast tomosynthesis (DBT) is often inadequate for screening women with a personal history of breast cancer (PHBC). The ongoing prospective Tomosynthesis or Contrast-Enhanced Mammography, or TOCEM, trial includes three annual screenings with both DBT and contrast-enhanced mammography (CEM). Purpose To perform interim assessment of cancer yield, stage, and recall rate when CEM is added to DBT in women with PHBC. Materials and Methods From October 2019 to December 2022, two radiologists interpreted both examinations: Observer 1 reviewed DBT first and then CEM, and observer 2 reviewed CEM first and then DBT...
April 2024: Radiology